Bavarian Nordic — Update 26 April 2016

Bavarian Nordic — Update 26 April 2016

Bavarian Nordic

Analyst avatar placeholder

Written by

Bavarian Nordic

Private placement trumps IPO

Funding update

Pharma & biotech

26 April 2016

Price

DKK265

Market cap

DKK8,162m

US$/DKK6.56

Net pro forma cash (DKKm) at December 2015 + raise

1,658

Shares in issue

30.8m

Free float

100%

Code

BAVA

Primary exchange

NASDAQ OMX Copenhagen

Secondary exchange

US OTC Pink (ADR)

Share price performance

%

1m

3m

12m

Abs

7.4

(11.4)

(22.5)

Rel (local)

6.0

(11.5)

(20.0)

52-week high/low

DKK360

DKK228

Business description

Bavarian Nordic is a Danish biotech focused on developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Its lead products are Prostvac (prostate cancer) partnered with Bristol Myers Squibb and Imvamune (smallpox).

Next events

Q116 results

13 May 2016

MVA-BN RSV Ph I data

Q216

CV-301+nivo Ph II start

H216

Prostvac Ph III data

2017

Analysts

Lala Gregorek

+44 (0) 20 3681 2527

Juan Pedro Serrate

+44 (0) 20 3681 2534

Bavarian Nordic is a research client of Edison Investment Research Limited

The current weak US IPO conditions have resulted in a slight change of plan for Bavarian Nordic. It recently shelved its US listing plans and instead completed a private share placement, which raised c $100m vs the expected $86m in the F-1 filing. New funds will be used for the same purposes as the IPO, namely advancing the development of CV-301, MVA-BN RSV and for capex. Prostvac has passed its first interim analysis and the Phase III trial will continue without modification.

Year end

Revenue
(DKKm)

PBT*
(DKKm)

EPS*
(DKK)

DPS
(DKK)

P/E
(x)

Yield
(%)

12/14

1,217

110

0.27

0.0

N/A

N/A

12/15

1,021

80

0.22

0.0

N/A

N/A

12/16e

1,020

(121)

(0.42)

0.0

N/A

N/A

12/17e

2,560

1,423

4.53

0.0

N/A

N/A

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

Private placement completed, cash inflow increases

Instead of a public offering, Bavarian Nordic has closed a private offering of 2.77m shares (almost 9% of issued shares after the offering) at a price of DKK240 per share raising approximately DKK665 in gross proceeds. As a result, the company expects to exit 2016 with a cash preparedness position of DKK1.9bn which comprises cash and equivalents, offering proceeds and undrawn credit lines.

Smart move adapting to current market conditions

We view Bavarian’s decision as a smart one given the fact that public markets have been hostile to biotech companies lately. The private offering was oversubscribed due to strong support from existing shareholders, as well as new European and US investors, and raised more funds than originally planned in the US IPO. This demonstrates that Bavarian’s investment case as a well-funded revenue-generating company with an interesting pipeline, resonates with investors.

Valuation: rNPV of DKK12.97bn or DKK421/share

We are updating our valuation to DKK12.97bn or DKK421/share (down from DKK12.04bn or DKK430/share) on account of rolling forward in time, updating net cash and a strengthening DKK/US$ rate. With an improved cash runway, there is now more clarity on development plans/timelines for MVA-BN RSV and CV-301. RSV is a significant opportunity; however, in the absence of clinical data, we do not yet include a contribution for MVA-BN RSV. CV-301, which has clinical data and will be tested in three oncology indications, is now included in our valuation. Further insight into the clinical programme for MVA-BN Brachyury (not yet included in our valuation) and additional income from J&J for MVA-BN Filovirus and MVA-BN HPV represent further upside.

Cash boost to increase long-term value

Bavarian Nordic has raised DKK665m from new and existing investors in a private offering and, although a future NASDAQ IPO is still a possibility longer term, this private placement leaves the company well funded for an eventful year. In fact, the strategic rationale for a US IPO remains intact as US investors have participated in the follow-on offering. With these funds, Bavarian Nordic plans to expedite the development of two key programmes: MVA-BN RSV and CV-301, along with investment in manufacturing capabilities for clinical studies and commercial-scale production, in particular for future government orders of Imvamune. This is part of the company’s strategy to create long-term value.

As mentioned, proceeds from the offering will be used in the further development of clinical-stage candidates MVA-BN RSV and CV-301. With respect to the RSV (respiratory syncytial virus) programme, results from a Phase I trial in healthy volunteers are expected by mid-2016, with a potential initiation of Phase II testing in the second half of the year. The RSV vaccine represents a significant commercial opportunity as RSV infection causes more than 177,000 hospitalisations in the elderly every year, plus an additional 100,000 in children. Further market information can be found in our update note published in August 2015. The fact that this programme uses the same vector as Imvamune, which has previously reported no safety issues, gives confidence in the successful completion of the Phase I trial and advancement to Phase II studies.

With regard to the CV-301 cancer immunotherapy, Bavarian Nordic will use the funds to study the product in three cancer indications. Non-small cell lung cancer (NSCLC) has been prioritised as the lead indication and a Phase II trial of CV-301 in combination with PD-1 (programmed cell death-1) inhibitor nivolumab will start in H216. Recent advances in immuno-oncology have highlighted the potential to combine CV-301 with a PD-1 checkpoint inhibitor to improve efficacy. There are a large number of lung cancer patients who could benefit from a CV-301/checkpoint inhibitor approach and potential for trials based on shorter endpoints such as overall response rate and progression-free survival to rapidly establish proof-of-concept. Other studies in bladder and colorectal cancer are slated to start in H117, although the design of all three studies is still to be confirmed.

Other recent news includes publication of positive Phase I data of the Ebola vaccine in the Journal of the American Medical Association (JAMA).1 This programme is partnered with Janssen and is part of a global private-public partnership in which Bavarian Nordic’s MVA-BN technology is used as part of a prime boost regimen with Janssen’s AdVac to enhance immune response. In the trial, 21 days after the boost with MVA-BN, 100% of participants (n=87) generated Ebola-specific antibodies with no serious adverse events reported, and at eight-month follow-up, all participants were producing antibodies to Ebola.

Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines A Randomized Clinical Trial http://jama.jamanetwork.com/article.aspx?articleid=2514196.

However, the main value driver is the prostate cancer vaccine Prostvac. The first interim analysis (at 40% of the number of events for final overall survival analysis, or 214 events) of the three event-driven analyses has already occurred; the second (at 60% or 321 events) is likely to happen in H216 and the final one (at 80% or 427 events) at the end of 2016/early 2017 ahead of final data readout (534 events) in 2017. The programme is partnered with Bristol-Myers Squibb (BMS) in an option deal that could be worth up to $1bn depending on survival data, regulatory milestones and sales performance. In addition, BMS will study Prostvac in two Phase II trials in combination with its own checkpoint inhibitors, ipilimumab and nivolumab.

Prostvac is undergoing several Phase II studies in collaboration with the US National Cancer Institute (NCI), two of which will read out this year: a combination trial with enzalutamide (Xtandi, Medivation/Astellas) in early prostate cancer and a monotherapy trial as neoadjuvant in localised prostate cancer. A comprehensive overview of Bavarian’s clinical cancer programmes will be provided at ASCO 2016 on 4 June at an investor and analyst reception.

Valuation

Our updated Bavarian Nordic sum-of-the parts valuation stands at DKK12.97bn or DKK421/share (previously DKK12.04bn or DKK430/share). We have rolled our valuation forward in time and updated the number of shares outstanding to 30.8m to include the new shares from the capital increase. Other specific changes to our valuation are the inclusion of two additional indications for CV-301, NSCLC and bladder cancer, in addition to mCRC, now that the company has a clear development path for the product and the funds to execute it. We continue to assume that Bavarian Nordic will out-license this programme for commercialisation. We have updated our end-FY16 forecast cash to include the net proceeds from the private offering and FX rates, which reflect the strengthening of the Danish kroner (now US$/DKK6.56 vs DKK6.62 previously). We summarise the components of our valuation in Exhibit 1. All product valuations represent the present value of future cash flows forecast for each product, risk-adjusted where appropriate, and then taxed.

At this stage, we do not include a contribution for MVA-BN RSV, as it is in Phase I and assessing its potential, in the absence of any clinical data, is challenging. However, as highlighted in our previous update note, there are no approved RSV vaccines and this could be a significant opportunity, hence it represents pure upside potential to our valuation. For a similar reason we do not include MVA-BN Brachyury; Phase I data are available, although this immunotherapy has broad potential and the cancer types in which further development is planned have not yet been disclosed.

Other sources of potential upside come from additional income for MVA-BN Filovirus and MVA-BN HPV from existing deals with J&J; our valuation includes the upfront payment of DKK59m from the HPV deal, but does not capture additional milestones or any future royalty contributions, or the potential for any contract extensions, all of which are possible.

Exhibit 1: Bavarian Nordic sum-of-the-parts valuation

Value driver

Value (DKKm)

Value/share (DKK)

Key assumptions

Prostvac (CRPC)

9,139

302.2

Launch: 2018. Peak sales: $2.6bn. Price: $50k pa. Probability of success: 65%. Effective royalty: 30%.

Imvamune/Imvanex

3,039

98.6

Includes expected revenues under existing contracts (US and Canada) in addition to risk-adjusted forecasts for future contracts (US, Canada and EU). US average price of $28.5; assume premium price ex-US. WACC of 10% as limited development risk (approved in EU and Canada).

MVA-BN FiloVirus (J&J)

26

0.8

Includes future payments under existing J&J deal; excludes future royalty payments or contract extensions.

MVA-BN HPV (J&J)

42

1.4

Includes US$9m upfront payment (to be recognised in 2016); excludes future development and regulatory milestones and future royalty payments.

CV-301 (NSCLC)

126

4.1

Launch: 2020. Peak sales: $292m. Price: $50k pa. Probability of success: 25%. Royalty: 20%.

CV-301 (mCRC)

299

9.7

Launch: 2021. Peak sales: $883m. Price: $50k pa. Probability of success: 25%. Royalty: 20%.

CV-301 (bladder cancer)

152

4.9

Launch: 2021. Peak sales: $450m. Price: $50k pa. Probability of success: 25%. Royalty: 20%.

R&D

(1,118)

(36.2)

Risk-adjusted future R&D spend.

SG&A

(538)

(17.5)

Risk-adjusted future SG&A spend.

Net cash

1,625

52.7

End-December 2015 cash plus net private placement proceeds.

Total

12,972

420.7

Source: Edison Investment Research. Note: DCF out to 2027; WACC of 12.5% (unless specified). US$/DKK6.56.

The successful closing of the DKK655m private placement provides greater financial resources to advance the development of MVA-BN RSV and CV-301. We await further disclosures from the company regarding trial design and timelines, which will inform our assumptions for future commercial potential (and future R&D spending), as well as our assessment of the economics of downstream licensing deals. We will update our valuation when this information is forthcoming.

Financials

We have updated our model with the FY15 results and 2016 guidance, while we await Q116 results on 13 May. The company has guided that it expects 2016 revenues to be c DKK1bn, most of it in the second half of the year, and break-even EBIT. Most of the revenues (DKK 750m) will come from US government orders of Imvamune, whereas a quarter will come from R&D contracts along with the Ebola/Marburg partnership with Janssen. Bavarian Nordic also expects to incur R&D costs of DKK580m, of which DKK475m will be incurred in the P&L. We have also updated our model to reflect the recent cash raise.

Exhibit 2: Bavarian Nordic financial guidance versus Edison estimates for 2016 (DKKm)

Measure

Guidance

New Edison estimates

Old Edison estimates

Revenue

1,000

1,020

1,299

EBIT

0

(152)

137

Cash preparedness*

1,900

1,994

1,394

P&L R&D costs

475

472.5

387

Source: Edison Investment Research; Bavarian Nordic. Note: *Cash preparedness includes cash, cash equivalents and credit lines.

According to FY15 results, Bavarian Nordic had cash and cash equivalents of DKK1bn, which increase to DKK1.5bn with the addition of readily available credit lines. Of the total revenues of DKK1bn, most came from the sale of bulk drug substance for MVA-BN Filo to Janssen, worth DKK762m, and the rest from the sale of Imvamune to the US and Canadian governments (DKK78m) and ongoing research and development contracts (DKK181m).

Bavarian Nordic received DKK631m prepayments from customers in 2015, of which DKK579m was recognised as revenue. These payments included two milestone payments from Janssen from the Eblola programme from 2014 and 2015 and US government orders of Imvamune from 2013 and 2014. Therefore, current deferred revenue on the balance sheet is DKK405m vs DKK375m at end 2014.

Exhibit 3: Financial summary

DKKm

2013

2014

2015

2016e

2017e

Year end 31 December

IFRS

IFRS

IFRS

IFRS

IFRS

PROFIT & LOSS

Revenue

 

 

1,213

1,217

1,021

1,020

2,560

Cost of Sales

(485)

(495)

(415)

(456)

(472)

Gross Profit

728

722

605

565

2,088

EBITDA

 

 

181

62

48

(127)

1,475

Operating Profit (before GW and except)

 

181

62

4

(127)

1,413

Intangible Amortisation

(148)

(46)

(3)

(25)

(6)

Other

0

0

0

0

0

Exceptionals

0

0

0

0

0

Operating Profit

33

17

2

(152)

1,407

Net Interest

(27)

48

76

7

10

Other

0

0

0

0

0

Profit Before Tax (norm)

 

 

154

110

80

(121)

1,423

Profit Before Tax (as reported)

 

6

64

78

(145)

1,417

Tax

(53)

(38)

(18)

(10)

(26)

Deferred tax

0

0

0

0

0

Profit After Tax (norm)

101

71

62

(131)

1,398

Profit After Tax (as reported)

(47)

26

59

(156)

1,391

Average Number of Shares Outstanding (m)

26.1

26.2

27.8

30.8

30.8

EPS - normalised (ore)

 

 

38.8

27.3

22.4

(42.4)

453.2

EPS - (IFRS) (ore)

 

 

(17.9)

9.9

21.4

(50.5)

451.1

Dividend per share (ore)

0.0

0.0

0.0

0.0

0.0

Gross Margin (%)

60.0

59.3

59.3

55.3

81.6

EBITDA Margin (%)

15.0

5.1

4.7

(12.5)

57.6

Operating Margin (before GW and except.) (%)

15.0

5.1

.4

(12.5)

55.2

BALANCE SHEET

Fixed Assets

 

 

552

568

585

600

557

Intangible Assets

105

109

108

113

107

Tangible Assets

323

337

326

346

335

Other

124

122

151

141

115

Current Assets

 

 

900

1,319

1,404

1,841

2,922

Stocks

234

122

91

187

194

Cash

532

980

1,058

1,416

2,238

Debtors

135

218

185

168

421

Other

0

0

70

70

70

Current Liabilities

 

 

(389)

(583)

(590)

(572)

(192)

Creditors

(381)

(581)

(588)

(570)

(190)

Short term borrowings

(8)

(2)

(2)

(2)

(2)

Long Term Liabilities

 

 

(87)

(52)

(57)

(57)

(57)

Long term borrowings

(72)

(33)

(31)

(31)

(31)

Other long term liabilities

(15)

(19)

(25)

(25)

(25)

Net Assets

 

 

976

1,252

1,342

1,814

3,231

CASH FLOW

Operating Cash Flow

 

 

160

346

78

(198)

873

Net Interest

(11)

15

41

7

10

Tax

(2)

(22)

(14)

(1)

(10)

Capex

(155)

(106)

(60)

(50)

(51)

Acquisitions/disposals

2

0

1

0

0

Financing

0

265

29

600

0

Dividends

0

0

0

0

0

Other

0

0

0

0

0

Net Cash Flow

(7)

498

75

358

821

Opening net debt/(cash)

 

 

(461)

(452)

(945)

(1,025)

(1,383)

HP finance leases initiated

0

0

0

0

0

Exchange rate movements

0

(0)

(22)

0

0

Other

(2)

(5)

27

0

(0)

Closing net debt/(cash)

 

 

(452)

(945)

(1,025)

(1,383)

(2,204)

Source: Edison Investment Research, company accounts

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER
Copyright 2016 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Bavarian Nordic and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.
Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited (“FTSE”) © FTSE 2016. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 9258 1161

Level 25, Aurora Place

88 Phillip St, Sydney

NSW 2000, Australia

Wellington +64 (0)48 948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 9258 1161

Level 25, Aurora Place

88 Phillip St, Sydney

NSW 2000, Australia

Wellington +64 (0)48 948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand

Liquefied Natural Gas Ltd — Update 26 April 2016

Liquefied Natural Gas Ltd

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free